Skip to content
BOLUS

Signal from the log

Remepy

36 M$ · Series A · Israel · Health software

Société israélienne qui associe un médicament sur ordonnance à une application thérapeutique personnalisée pilotée par intelligence artificielle, ce qu'elle appelle un médicament hybride. Son programme Hybridopa entre en phase 3 mondiale contre la maladie de Parkinson au quatrième trimestre 2026, après une phase 2a montrant une amélioration des symptômes moteurs et non moteurs.

Verified

Announced on , logged by the watch of 12 August 2026.

Operation
Funding round
Announced amount
36 M$
Stage
Series A
Country
Israel
Sector
Health software

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by O.G. Venture Partners , M Ventures , with NFX , Vine Ventures , Qumra Capital , TechAviv , 97212 Ventures , Fresh Fund , PsyMed Ventures , Key1 Capital , IT-Farm

Provenance
Source axios,prnewswire,pulse2
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).